Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries
Open Access
- 1 March 2024
- journal article
- research article
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 38, 100838
Abstract
No abstract availableKeywords
This publication has 80 references indexed in Scilit:
- NSCLC molecular testing in Central and Eastern European countriesBMC Cancer, 2018
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)Cancer Discovery, 2017
- Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBLVirchows Archiv, 2016
- RAS isoforms and mutations in cancer at a glanceJournal of Cell Science, 2016
- MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met OverexpressionJournal of Clinical Oncology, 2016
- Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6The Lancet Oncology, 2015
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung CancerNew England Journal of Medicine, 2014
- Drugging the undruggable RAS: Mission Possible?Nature Reviews Drug Discovery, 2014
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactionsNature, 2013